文献速递神经重症与神经感染

生酮/间歇性禁食饮食在胶质瘤患者中的可行性与生物学活性

Feasibility and Biological Activity of a Ketogenic/Intermittent-Fasting Diet in Patients With Glioma.
PubMed 文献 · Neurology · 2021-07-07

饮食耐受良好,出现2例3级不良事件(中性粒细胞减少、癫痫发作)。系统性活性指标(HbA1c、胰岛素、脂肪体重)显著下降,瘦体重增加;磁共振波谱显示肿瘤和对侧脑内酮体浓度较基线升高,平均酮尿与脑内酮体相关。

要点

  • 饮食引起系统性代谢改变:HbA1c、胰岛素和脂肪体重下降,瘦体重增加。
  • 酮尿与脑内酮体浓度相关,可能比食物记录更好地反映系统性活性。

核心结论

  • GLAD饮食干预虽然要求严格,但在胶质瘤患者中产生了有意义的酮尿和显著的系统性与脑内代谢改变。
  • 酮尿与脑内酮体浓度相关,且似乎比患者报告的食物记录更好地反映系统性活性。

研究设计与样本

  • 干预为8周Glioma Atkins-Based Diet(GLAD):每周2天禁食(热量<20%计算需求)与5天改良Atkins饮食(净碳水化合物≤20 g/d)交替。
  • 主要结局为通过食物记录评估的饮食依从性。

主要发现

  • 饮食耐受良好,出现2例3级不良事件(中性粒细胞减少、癫痫发作)。
  • 系统性活性指标包括HbA1c、胰岛素和脂肪体重显著下降,瘦体重增加。
  • 磁共振波谱显示肿瘤和对侧脑内酮体浓度(β-羟丁酸和丙酮)较基线升高。
  • 平均酮尿与肿瘤和对侧脑内β-羟丁酸相关(R s = 0.52,p = 0.05)。

关键数值与推荐

  • GLAD饮食:每周2天禁食(热量<20%计算需求)与5天改良Atkins饮食(净碳水化合物≤20 g/d)交替,持续8周。
  • 尿乙酰乙酸≥40 mg/dL定义为达到有意义的酮尿。

临床怎么用

  • GLAD饮食可作为胶质瘤患者的一种可行饮食干预,但需注意其要求严格且可能发生3级不良事件。
  • 尿酮体监测可能比食物记录更可靠地反映饮食的系统性生物学活性。

局限性

  • 依从性通过食物记录评估,可能存在报告偏倚。
  • 异柠檬酸脱氢酶突变型胶质瘤亚组分析在控制酮尿后未显示脑内代谢物差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To examine the feasibility, safety, systemic biological activity, and cerebral activity of a ketogenic dietary intervention in patients with glioma. METHODS: Twenty-five patients with biopsy-confirmed World Health Organization grade 2 to 4 astrocytoma with stable disease after adjuvant chemotherapy were enrolled in an 8-week Glioma Atkins-Based Diet (GLAD). GLAD consisted of 2 fasting days (calories <20% calculated estimated needs) interleaved between 5 modified Atkins diet days (net carbohydrates ≤20 g/d) each week. The primary outcome was dietary adherence by food records. Markers of systemic and cerebral activity included weekly urine ketones, serum insulin, glucose, hemoglobin A1c, insulin-like growth factor-1, and magnetic resonance spectroscopy at baseline and week 8. RESULTS: Twenty-one patients (84%) completed the study. Eighty percent of patients reached ≥40 mg/dL urine acetoacetate during the study. Forty-eight percent of patients were adherent by food record. The diet was well tolerated, with two grade 3 adverse events (neutropenia, seizure). Measures of systemic activity, including hemoglobin A1c, insulin, and fat body mass, decreased significantly, while lean body mass increased. Magnetic resonance spectroscopy demonstrated increased ketone concentrations (β-hydroxybutyrate [bHB] and acetone) in both lesional and contralateral brain compared to baseline. Average ketonuria correlated with cerebral ketones in lesional (tumor) and contralateral brain (bHB R s = 0.52, p = 0.05). Subgroup analysis of isocitrate dehydrogenase-mutant glioma showed no differences in cerebral metabolites after controlling for ketonuria. CONCLUSION: The GLAD dietary intervention, while demanding, produced meaningful ketonuria and significant systemic and cerebral metabolic changes in participants. Ketonuria in participants correlated with cerebral ketone concentration and appears to be a better indicator of systemic activity than patient-reported food records. TRIAL REGISTRATION INFORMATION: ClinicalTrials.gov Identifier: NCT02286167.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Schreck KC, Hsu FC, Berrington A, et al. Feasibility and Biological Activity of a Ketogenic/Intermittent-Fasting Diet in Patients With Glioma. Neurology. 2021. PMID: 34233941. doi:10.1212/WNL.0000000000012386

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。